Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOLAF trial of durvalumab + olaparib + fulvestrant in HRR-altered ER-positive/HER2-negative advanced breast cancer
2024-516847-23-00Phase 2Authorised
- Sponsor
- Unicancer
- Start
- Oct 2024
- Modality
- Small Molecules, Peptides, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, olaparib, fulvestrant and goserelin in breast cancer, sponsored by Unicancer. Primary endpoint: Progression-free survival rate at 24 weeks. Planned start Oct 2024; status: authorised.
02
Drugs
durvalumabolaparibfulvestrantgoserelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-516847-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516847-23-00.